Evidence map›Paper›PMID 39998211›Full record

ArticlemBio2025

Mefloquine reduces the bacterial membrane fluidity of

Nagendran Tharmalingam, Harikrishna Sekar Jayanthan, Jenna Port, Fernanda Cristina Possamai Rossatto, Eleftherios Mylonakis

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Nagendran TharmalingamHouston Methodist Hospital and Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0001-6107-3754
Harikrishna Sekar JayanthanVanderblit University, Nashville, Tennessee, USA.
Jenna PortTufts University, Boston, Massachusetts, USA.
Fernanda Cristina Possamai RossattoHouston Methodist Hospital and Houston Methodist Research Institute, Houston, Texas, USA.
Eleftherios MylonakisHouston Methodist Hospital and Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0002-4624-0777

Funding

Technical Mother Machine CoreP01AI083214 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI David C Hooper · 2009 to 2026
$39.4M
NIAID NIH HHS P01 AI083214
6 · The paper itself

Abstract

IMPORTANCE: Antimicrobial resistance is a threat globally, and new treatments are urgently needed to combat the rise of multidrug-resistant bacteria. However, the development of anti-infectives has declined over the last two decades due to regulatory, financial and long-term requirement related challenges. In this study, we examined the membrane interactions of the antiparasitic agent mefloquine (MFQ) in combination with polymyxin B, using both

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsCell MembraneMefloquineMembrane FluidityPolymyxin BAcinetobacter InfectionsAnimalsCell Membrane PermeabilityDrug SynergismMicrobial Sensitivity TestsStructure-Activity RelationshipAnti-Bacterial AgentsMefloquinePolymyxin BA. baumanniiantibiotic resistancemefloquinepolymyxinsynergy

Identifiers

PMID39998211
PMCPMC11980597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.